RxDoctor Payments DataLook up a doctor →

Jamiel Ambrad, MD

Family Medicine · Wakefield, RINPI 1720076011

Payments from drug & device makers

$18,000in general payments, 2019–2025

Across 1,134 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • AstraZeneca$3K
  • Novo Nordisk$1K
  • Pfizer$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$863
  • Lilly USA, LLC$796
  • plus $7K from 36 others

What the payments were for

  • Food & beverage$18,000100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,000 in reported general payments places this provider in the 95th percentile of 222 family medicine providers in Rhode Island.

See all family medicine providers in Rhode Island

Medicare billing

Part B allowed, 2024
$65,142
Medicare patients
204
Services billed
689

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide91$91,032
EliquisApixaban51$51,624
JardianceEmpagliflozin78$49,403
MounjaroTirzepatide36$37,057
RybelsusSemaglutide31$37,024
UbrelvyUbrogepant24$28,552
JanuviaSitagliptin Phosphate25$26,112
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$23,341
XareltoRivaroxaban22$23,154
OxycontinOxycodone Hcl13$20,240
FarxigaDapagliflozin Propanediol34$19,959
Tresiba Flextouch U-100Insulin Degludec26$16,864
Breo ElliptaFluticasone/Vilanterol34$15,957
MyrbetriqMirabegron29$12,877
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog25$12,471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,442$128,056122 claims
Boehringer IngelheimJardiance, Jentadueto$725$57,89394 claims
PfizerEliquis$1,360$51,62451 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$659$48,71685 claims
Lilly USA, LLCMounjaro$796$37,05736 claims
AbbVieUbrelvy, Synthroid$3,561$32,26971 claims
MerckJanuvia$499$26,11225 claims
Johnson & JohnsonXarelto$288$23,15422 claims
AstraZenecaFarxiga$2,535$19,95934 claims
Astellas Pharma US IncMyrbetriq$55$12,87729 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 222 family medicine providers in Rhode Island.

Other family medicine in Wakefield

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →